Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Metoprolol- Toprol XL · 1 trial · 1 indication
Assesment following multiple dosing of metoprolol CR/XL 200 mg once daily, or multiple dosing of metoprolol IR 200 mg daily in divided doses
Assesment following multiple dosing of metoprolol CR/XL 200 mg once daily, or multiple dosing of metoprolol IR 200 mg daily in divided doses
| Arm | Type | Description |
|---|---|---|
| Metoprolol- Toprol XL | EXPERIMENTAL | Metoprolol extended release (CR/XL) tablet 200 mg once daily |
| Metoprolol- Lopressor | ACTIVE_COMPARATOR | Metoprolol immediate release (IR) tablet |
| Name | Type | Description |
|---|---|---|
| Metoprolol- Toprol XL | DRUG | Extended release tablet, 200mg once daily for 4 days |
| Metoprolol- Lopressor | DRUG | Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily |
Inclusion Criteria: * Male and female patients admitted to the CCU with suspected acute myocardial infarction * Age 18 years or older * Treated with and tolerated the full dose of metoprolol IR 50 mr four times daily or metoprolol CR/XL 200 mg once daily on study day 1 * Expected to stay in the CCU...
Metoprolol-Toprol XL is being studied for use in acute myocardial infarction, commonly known as a heart attack. The clinical development program in this indication is at Phase 1, with one completed pharmacokinetic and pharmacodynamic study conducted in patients with acute myocardial infarction.
AstraZeneca PLC, which trades under the ticker AZN, is the developer associated with Metoprolol-Toprol XL. The company is listed as the sponsor of the Phase 1 pharmacokinetic and pharmacodynamic study of the drug in acute myocardial infarction.
Metoprolol-Toprol XL is in Phase 1 development for acute myocardial infarction. One Phase 1 trial has been completed, and no trials are currently active. The program is investigational and has not been approved for this indication based on the available development information.
Metoprolol-Toprol XL has been evaluated in one completed Phase 1 trial, NCT01523054, titled Metoprolol in Acute Myocardial Infarction. A PK/PD Study. The trial enrolled 27 patients, was randomized, used an active control, and was not double blind.
Metoprolol-Toprol XL is a small molecule. It was evaluated in a Phase 1 pharmacokinetic and pharmacodynamic study in patients with acute myocardial infarction, a study design used to characterize how the body processes the drug and how the drug affects the body.